Gemcitabine and R115777 (Tipifarnib) Combination Therapy for Metastatic Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 27 Jan 2018
At a glance
- Drugs Gemcitabine (Primary) ; Tipifarnib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 27 Jan 2018 Primary endpoint (Objective response rate (ORR)) has not been met, as per results published in the Investigational New Drugs.
- 27 Jan 2018 Results assessing efficacy of combination of tipifarnib and gemcitabine published in the Investigational New Drugs.
- 01 Jul 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.